gdc

Cholangiocarcinoma

Comparing Primary Tumor, Metastatic Tumor Tissue, and  Liquid Biopsy in Patients with Intrahepatic Cholangiocarcinoma: Genomic Profiling Study
Cholangiocarcinoma
Genomic alterations (mutations) characteristic of intrahepatic cholangiocarcinoma (CCA) are well-known. In this study, Jeffrey S. Ross, MD, Medical Director, Foundation Medicine, Cambridge, Massachusetts, and colleagues examined whether genomic alterations in intrahepatic CCA of a primary tumor would differ from those found in tissue from a tumor that has metastasized (spread) to other parts of the body and the alterations that are found with liquid biopsy (a test done using a blood sample).
The ClarIDHy Study: IDH1 Mutation Detection in Plasma  Circulating Tumor-Cell DNA and Clinical Response  in Patients with Advanced Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma
The feasibility of IDH1 mutation detection in plasma circulating tumor-cell DNA from patients with intrahepatic cholangiocarcinoma (CCA) was demonstrated.
Combination Immunotherapy with Opdivo and Yervoy in Patients with Advanced Biliary Tract Cancer
Cholangiocarcinoma
The combination of the PD-1 inhibitor Opdivo (nivolumab) and the CTLA-4 inhibitor Yervoy (ipilimumab) has been effective therapy for some types of solid tumor cancers, such as melanoma and lung cancer.
Clinical Trial of Futibatinib, an FGFR Inhibitor, in Patients with Intrahepatic Cholangiocarcinoma Harboring  FGFR2 Gene Fusions or Other Rearrangements
Cholangiocarcinoma
Preliminary results were presented from this phase 2 clinical trial by Lipika Goyal, MD, MPhil, Medical Oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital, Boston, at the 2020 ASCO annual meeting.
Comparing the Combination of 2 Immunotherapies versus Immunotherapy plus Chemotherapy as First-Line Treatment for Patients with Advanced Unresectable Biliary Tract Cancer
Cholangiocarcinoma
In a phase 2 clinical trial, 2 different combinations were studied and compared for use as the first treatments given to patients with cholangiocarcinoma (CCA).
Natural History of Cholangiocarcinoma with FGFR Mutations
Cholangiocarcinoma
Genetic alterations in the FGFR pathway are emerging as promising therapeutic targets in patients with cholangiocarcinoma (CCA). A retrospective chart review (or a medical record review) was performed in patients with CCA who were found to have an FGFR mutation during molecular profiling of the tumor as part of routine care for CCA.
Biomarker Testing Crucial for Patients with Cholangiocarcinoma
BiomarkersCholangiocarcinomaGenetics & Cancer
New treatments are becoming available for patients with cholangiocarcinoma (bile duct cancer). Testing for specific biomarkers is crucial to ensure each patient receives the best available treatment for any associated biomarker.
Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
CholangiocarcinomaFDA Approvals, News & Updates
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion.
February Is Gallbladder and Bile Duct Cancer Awareness Month
CholangiocarcinomaSlideshows
View this slideshow to learn important facts about Gallbladder and bile duct cancer, including statistics, causes and symptoms.
Page 1 of 2
Results 1 - 10 of 11

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country